WallStSmart

MP Materials Corp (MP)vsVersamet Royalties Corporation Common Stock (VMET)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MP Materials Corp generates 529% more annual revenue ($347.57M vs $55.27M). VMET leads profitability with a 58.4% profit margin vs -20.5%. VMET earns a higher WallStSmart Score of 58/100 (C).

MP

Avoid

28

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 4.0Quality: 7.5
Piotroski: 4/9Altman Z: 1.53

VMET

Buy

58

out of 100

Grade: C

Growth: 10.0Profit: 8.5Value: 4.7Quality: 7.5
Piotroski: 5/9Altman Z: 1.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MPSignificantly Overvalued (-64.3%)

Margin of Safety

-64.3%

Fair Value

$37.06

Current Price

$56.51

$19.45 premium

UndervaluedFair: $37.06Overvalued

Intrinsic value data unavailable for VMET.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MP1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
118.6%10/10

Revenue surging 118.6% year-over-year

VMET5 strengths · Avg: 9.8/10
Profit MarginProfitability
58.4%10/10

Keeps 58 of every $100 in revenue as profit

Operating MarginProfitability
90.6%10/10

Strong operational efficiency at 90.6%

Revenue GrowthGrowth
594.0%10/10

Revenue surging 594.0% year-over-year

EPS GrowthGrowth
573.0%10/10

Earnings expanding 573.0% YoY

Debt/EquityHealth
0.129/10

Conservative balance sheet, low leverage

Areas to Watch

MP4 concerns · Avg: 2.5/10
Altman Z-ScoreHealth
1.534/10

Distress zone — elevated risk

Return on EquityProfitability
-3.0%2/10

ROE of -3.0% — below average capital efficiency

EPS GrowthGrowth
-55.6%2/10

Earnings declined 55.6%

Free Cash FlowQuality
$-79.28M2/10

Negative free cash flow — burning cash

VMET3 concerns · Avg: 3.0/10
P/E RatioValuation
37.5x4/10

Premium valuation, high expectations priced in

Market CapQuality
$1.26B3/10

Smaller company, higher risk/reward

Altman Z-ScoreHealth
1.192/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : MP

The strongest argument for MP centers on Revenue Growth. Revenue growth of 118.6% demonstrates continued momentum.

Bull Case : VMET

The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 58.4% and operating margin at 90.6%. Revenue growth of 594.0% demonstrates continued momentum.

Bear Case : MP

The primary concerns for MP are Altman Z-Score, Return on Equity, EPS Growth.

Bear Case : VMET

The primary concerns for VMET are P/E Ratio, Market Cap, Altman Z-Score.

Key Dynamics to Monitor

MP profiles as a hypergrowth stock while VMET is a growth play — different risk/reward profiles.

VMET is growing revenue faster at 594.0% — sustainability is the question.

VMET generates stronger free cash flow (13M), providing more financial flexibility.

Monitor OTHER INDUSTRIAL METALS & MINING industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VMET scores higher overall (58/100 vs 28/100), backed by strong 58.4% margins and 594.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

MP Materials Corp

BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA

MP Materials Corp. The company is headquartered in Las Vegas, Nevada.

Versamet Royalties Corporation Common Stock

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Viamet Pharmaceuticals Corp (VMET) is a biopharmaceutical company focused on developing cutting-edge therapeutics for serious diseases, leveraging its proprietary metalloenzyme-based technology platform. The company is committed to addressing significant unmet medical needs in fungal infections and oncology, positioning itself as a leader in therapeutic innovation. With a diverse pipeline bolstered by strategic collaborations and a strong intellectual property portfolio, Viamet is well-prepared to advance its clinical initiatives and enhance shareholder value, aiming to redefine treatment approaches in its specialized therapeutic areas.

Want to dig deeper into these stocks?